VRDN logo

Viridian Therapeutics, Inc. Stock Price

NasdaqCM:VRDN Community·US$1.7b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

VRDN Share Price Performance

US$20.99
-2.55 (-10.83%)
US$20.99
-2.55 (-10.83%)
Price US$20.99

VRDN Community Narratives

There are no narratives available yet.

Recent VRDN News & Updates

Is Viridian Therapeutics (NASDAQ:VRDN) A Risky Investment?

Jul 01
Is Viridian Therapeutics (NASDAQ:VRDN) A Risky Investment?

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window

Mar 02

Is Viridian Therapeutics (NASDAQ:VRDN) Using Too Much Debt?

Feb 11
Is Viridian Therapeutics (NASDAQ:VRDN) Using Too Much Debt?

Viridian Therapeutics, Inc. Key Details

US$305.0k

Revenue

US$304.6m

Cost of Revenue

-US$304.3m

Gross Profit

-US$28.5m

Other Expenses

-US$275.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-3.38
Gross Margin
-99,761.97%
Net Profit Margin
-90,407.54%
Debt/Equity Ratio
4.0%

Viridian Therapeutics, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet and fair value.

2 Risks
2 Rewards

About VRDN

Founded
2010
Employees
143
CEO
Stephen Mahoney
WebsiteView website
www.viridiantherapeutics.com

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a loss of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›